Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

DNA Cleavage Properties, Antimicrobial and Cytotoxic Activity and 4D-QSAR Analysis of Some Pyrazole Derivatives

Author(s): Semiha Kopru, Fatma Ozturk Küp*, Nazmiye Sabanci, Mehmet Çadir, Duygu Cemre Bulut, Fatih Duman, Ilhan Ozer İlhan and Emin Saripinar*

Volume 16, Issue 8, 2019

Page: [904 - 918] Pages: 15

DOI: 10.2174/1570180815666180926104319

Price: $65

Abstract

Background: An extensive study of 19 pyrazole derivatives were carried out based on the evaluation of DNA cleavage properties, antimicrobial and cytotoxic activities and 4D-QSAR analysis including pharmacophore modelling and bioactivity prediction by the Electron Conformational-Genetic Algorithm (EC-GA) method.

Methods: The pyrazole derivatives were tested for their antimicrobial activity against certain human pathogenic organisms using the agar diffusion procedure. Binding of compounds with DNA was studied by gel electrophoresis using plasmid pBR322 DNA. The compounds were investigated for their properties as cytotoxic agents by brine shrimp lethality bioassay. To identify the pharmacophoric elements and find out the most important molecular properties which govern cytotoxic activity, multiple conformations of the compounds were used.

Results: The urea derivatives of pyrazole had higher antibacterial activities against Gram-negative bacteria than against Gram-positive bacteria. Many of the compounds were found to cleave plasmid pBR322 DNA from the supercoiled form to the nicked circular. The cytotoxicity values of the compounds ranged from 13.87 to 84.1 µg/mL. The generated QSAR model was evaluated through the use of the Leave-One-Out Cross Validation (LOO-CV) method. A statistically significant and considerably predictive QSAR model was obtained with 4- descriptors resulting in R2 training =0.8223, R2 test =0.9346, q2=0.6201, q2 ext1=0.8672, q2 ext2= 0.8662 and q2 ext3=0.9511.

Discussion: The generated model demonstrates that geometrical parameters are more correlated with cytotoxic activity. The resulting EC-GA model would provide benefits to design novel bioactive pyrazole derivatives which are more potent and have less side effects.

Conclusion: It is believed that the generated QSAR model gives insight into developing new more potent pyrazole derivative drugs.

Keywords: DNA cleavage, antimicrobial activity, cytotoxic activity, EC-GA method, 4D-QSAR, pyrazole.

« Previous Next »
Graphical Abstract

[1]
Li, M.; Zhao, B.X. Progress of the synthesis of condensed pyrazole derivatives. Eur. J. Med. Chem., 2014, 85, 311-340.
[2]
Khan, M.F.; Alam, M.M.; Verma, G.; Akhtar, W.; Akhter, M.; Shaquiquzzaman, M. The therapeutic voyage of pyrazole and its analogs: A review. Eur. J. Med. Chem., 2016, 120, 170-201.
[3]
Kelland, L.R. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur. J. Cancer, 2005, 41, 971-979.
[4]
Kategaonkar, A.H.; Shinde, P.V.; Kategaonkar, A.H.; Pasale, S.K.; Shingate, B.B.; Shingare, M.S. Synthesis and biological evaluation of new 2-chloro-3-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)quino- line derivatives via click chemistry approach. Eur. J. Med. Chem., 2010, 45, 3142-3146.
[5]
Zhang, Q-L.; Liu, J-G.; Chao, H.; Xue, G-Q.; Ji, L-N. DNA-binding and cleavage studies of novel binuclear copper(II) complex with 1,10-dimethyl-2,20-biimidazole ligand. J. Inorg. Biochem., 2001, 83, 49-55.
[6]
Solis, P.N.; Wright, C.W.; Anderson, M.M.; Gupta, M.P.; Phillipson, J.D. A microwell cytotoxicity assay using Artemia salina (brine shrimp). Planta Med., 1993, 59, 250-252.
[7]
Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
[8]
Hopfinger, A.J.; Wang, S.; Tokarski, J.S.; Jin, B.; Albuquerque, M.; Madhav, P.J.; Duraiswami, C. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc., 1997, 119, 10509-10524.
[9]
Vedani, A.; Dobler, M. 5D-QSAR: The key for simulating induced fit? J. Med. Chem., 2002, 45, 2139-2149.
[10]
Vedani, A.; Dobler, M.; Lill, M.A. Combining protein modeling and 6d-qsar. simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem., 2005, 48, 3700-3703.
[11]
Fujita, T.; Winkler, D.A. Understanding the roles of the “Two QSARs”. J. Chem. Inf. Model., 2016, 56, 269-274.
[12]
Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors, Methods and Principles in Medicinal Chemistry; Wiley-VCH: Weinheim, Germany, 2000, Vol. 11, .
[13]
Cho, S.J.; Hermsmeier, M.A. Genetic algorithm guided selection: variable selection and subset selection. J. Chem. Inf. Comput. Sci., 2002, 42, 927-936.
[14]
Zaheer-ul-Haq. Uddin, R.; Yuan, H.; Petukhov, P.A.; Choudhary, M.I.; Madura, J.D. Receptor-based modeling and 3d-qsar for a quantitative production of the butyrylcholinesterase inhibitors based on genetic algorithm. J. Chem. Inf. Model., 2008, 48, 1092-1103.
[15]
Özalp, A.; Yavuz, S.Ç.; Sabancı, N.; Çopur, F.; Kökbudak, Z.; Sarıpınar, E. 4D-QSAR investigation and pharmacophore identification of pyrrolo[2,1-c] [1,4] benzodiazepines using electron conformational-genetic algorithm method. SAR QSAR Environ. Res., 2016, 27, 317-342.
[16]
Yanmaz, E.; Saripinar, E.; Şahin, K.; Geçen, N.; Çopur, F. 4D-QSAR analysis and pharmacophore modeling: Electron conformational-genetic algorithm approach for penicillins. Bioorg. Med. Chem., 2011, 19, 2199-2210.
[17]
Sahin, K.; Saripinar, E.; Yanmaz, E.; Gecen, N. 4D-QSAR analysis and pharmacophore modeling: Propoxy methylphenyl oxasiazole. derivatives by electron conformatitional-genetic algorithm method. SAR QSAR Environ. Res., 2011, 22, 217-238.
[18]
Geçen, N.; Saripinar, E.; Yanmaz, E.; Şahin, K. Application of electron conformational-genetic algorithm approach to 1,4-dihydropyridines as calcium channel antagonists: pharmacophore identification and bioactivity prediction. J. Mol. Model., 2012, 18, 65-82.
[19]
Akyüz, L.; Saripinar, E.; Kaya, E.; Yanmaz, E. 4D-QSAR study of HEPT derivatives by electron conformational-genetic algorithm method. SAR QSAR Environ. Res., 2012, 23, 409-433.
[20]
Akyüz, L.; Saripinar, E. Conformation depends on 4D-QSAR analysis using EC–GA method: pharmacophore identification and bioactivity prediction of TIBOs as non-nucleoside reverse transcriptase inhibitors. J. Enzyme Inhib. Med. Chem., 2013, 28, 776-791.
[21]
İlhan, İ.; Çağlayan, A.; Önal, Z.; Akkoç, S.; Çadır, M. Reactions of Some Pyrazole-3-Carboxylic Acids and Carboxylic Acid Chlorides with Various O- and N- Nucleophiles. Lett. Org. Chem., 2013, 10, 602-610.
[22]
İlhan, İ.Ö.; Demirkol, K.; Önal, Z.; Akkoç, S.; Çadir, M. Functionalization Reactions of Various Pyrazole-3-carboxylic Acid Chlorides with Some Ureas. Asian J. Chem., 2014, 26, 2365-2368.
[23]
İlhan, İ.Ö.; Çadir, M.; Saracoglu, M.; Kandemirli, F.; Kökbudak, Z.; Akkoç, S. The Quantum Chemical and QSAR Studies for the Development of MRI Contrast. Chem. Sci. Rev. Lett., 2015, 4, 838-850.
[24]
Murray, P.R.; Baron, E.J.; Pfaller, M.A.; Tenover, F.C.; Yolken, R.H. Manual Clin. Microbiol., Wood, G.L.; Washington, J.A., (6th Edt). American Society for Microbiology. Washington, DC; , 1995. 308-316.
[25]
Gümüş, F.; Eren, G.; Açık, L.; Çelebi, A.; Öztürk, F.; Yılmaz, S.; Saǧkan, R.I.; Gür, S.; Özkul, A.; Elmalı, A. Synthesis, cytotoxicity, and DNA interactions of new cisplatin analogues containing substituted benzimidazole ligands. J. Med. Chem., 2009, 52, 1345-1357.
[26]
Rahman, A.; Choudhary, I.M.; Thomsen, W.J. Bioassay Techniques for Drug Development; Harwood Academic Publishers: Amsterdam, The Netherlands, 2001.
[27]
Bandgar, B.P.; Gawande, S.S.; Bodade, R.G.; Gawande, N.M.; Khobragade, C.N. Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents. Bioorg. Med. Chem., 2009, 17, 8168-8173.
[28]
Nikaido, H.; Vaara, M. Molecular basis of bacterial outer membrane permeability. Microbiol. Rev., 1985, 49, 1-32.
[29]
Déciga-Campos, M.; Rivero-Cruz, I.; Arriaga-Alba, M.; Castañeda-Corral, G.; Angeles-López, G.E.; Navarrete, A.; Mata, R. Acute toxicity and mutagenic activity of Mexican plants used in traditional medicine. J. Ethnopharmacol., 2007, 110, 334-342.
[30]
Patra, A.K.; Dhar, S.; Nethaji, M.; Chakravarty, A.R. Metal-assisted red light-induced DNA cleavage by ternary L-methionine copper(II) complexes of planar heterocyclic bases. Dalton Trans., 2005, 2, 896-902.
[31]
Gao, E.; Sun, Y.; Liu, Q.; Duan, L. An anticancer metallobenzylmalonate: crystal structure and anticancer activity of a palladium complex of 2,2′-bipyridine and benzylmalonate. J. Coord. Chem., 2006, 59, 1295-1300.
[32]
Naik, H.S. Synthesis and DNA binding studies of novel heterocyclic substituted quinoline schiff bases: a potent antimicrobial agent. Nucleosides Nucleotides Nucleic Acids, 2008, 27, 1197-1210.
[33]
Spartan’10; Wavefunction, Inc.: Irvine, CA, 2011.
[34]
Bersuker, I.B.; Bahceci, S.; Boggs, J.E.; Pearlman, R.S. An electron-conformational method of identification of pharmacophore and anti-pharmacophore shielding: Application to rice blast activity. J. Comput. Aided Mol. Des., 1999, 13, 419-434.
[35]
Bersuker, I.B.; Bahçeci, S.; Boggs, J.E. Improved electron-conformational method of pharmacophore identification and bioactivity prediction. Application to angiotensin converting enzyme inhibitors. J. Chem. Inf. Comput. Sci., 2000, 40, 1363-1376.
[36]
Saripinar, E.; Guzel, Y.; Patat, S.; Yildirim, I.; Akcamur, Y.; Dimoglo, A.S. Electron-topological investigation of structure-antitubercular activity relationship of thiosemicarbazone derivatives. Arzneimittelforschung, 1996, 46, 824-828.
[37]
Güzel, Y.; Saripinar, E.; Yilidrim, I. Electron-topological (ET) investigation of structure-antagonist activity of a series of dibenzo[a,d]cycloalkenimines. J. Mol. Struct: Theo. Chem, 1997, 418, 83-91.
[38]
Bersuker, I.B. Pharmacophore identification and quantitative bioactivity prediction using the electron-conformational method. Curr. Pharm. Des., 2003, 9, 1575-1606.
[39]
Consonni, V.; Ballabio, D.; Todeschini, R. Comments on the Definition of the Q2 Parameter for QSAR Validation. J. Chem. Inf. Model., 2009, 49, 1669-1678.
[40]
Lin, L.I.K. A concordance correlation coefficient to evaluate reproducibility. Biometrics, 1989, 45, 255-268.
[41]
Lin, L.I.K. Assay validation using the concordance correlation coefficient. Biometrics, 1992, 48, 599-604.
[42]
Chirico, N.; Gramatica, P. Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. J. Chem. Inf. Model., 2011, 51, 2320-2335.

Rights & Permissions Print Cite
Article Metrics
33
1
© 2024 Bentham Science Publishers | Privacy Policy